ClinicalTrials.gg

Program

VH4524184

A development code. Also written as “VH4524184 Formulation A IM” and “VH4524184 Formulation B IM”.

In GlaxoSmithKline's pipeline, HIV integrase inhibitor. Its studies are mostly in HIV Infections, led by GlaxoSmithKline.

Furthest: phase 2, since Jan 9, 20247 company-led studies, 3 open or runningNext primary completion: Oct 28, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline73 open or runningphase 2since Jan 9, 2024Nov 18, 2022Oct 28, 2027phase 2 · NCT07202546
  • Named in GlaxoSmithKline’s own pipeline as VH4524184, phase 2, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 18, 2022First study: phase 1 study in HIV InfectionsFirst studyNCT05631704 · 84 enrolled · United States
  2. Jan 9, 2024Phase 2 study in HIV InfectionsNCT06214052 · 22 enrolled · United States, Argentina, Canada and more
  3. Mar 1, 20242 phase 1 studies in HIV InfectionsNCT06310616, NCT06310551
  4. Jul 3, 2025Phase 1 study in HIV InfectionsNCT07066722 · 126 enrolled · United States
  5. Sep 30, 2025Phase 2 study in HIV InfectionsNCT07202546 · 186 planned · United States, Argentina, Australia and more
  6. May 29, 2026Phase 1 study in HIV InfectionsNCT07636928 · 9 planned · Netherlands
  7. Nov 5, 2026Primary completion moved from 2028-01-21 to 2029-05-28Date moved laterphase 1 · +16 months · NCT06310551
  8. Nov 12, 2026Primary completion moved from 2027-06-11 to 2027-10-28Date moved laterphase 2 · +5 months · NCT07202546

Ahead

  1. Oct 28, 2027Primary completion: phase 2 study in HIV InfectionsNCT07202546
  2. May 28, 2029Primary completion: phase 1 study in HIV InfectionsNCT06310551

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“HIV integrase inhibitor”the company's pipeline, read by Claude · source

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07636928HIV Infections · Netherlands1RecruitingAug 20, 20269
NCT07202546HIV Infections · United States, Argentina, Australia and more2RecruitingOct 28, 2027186
NCT07066722HIV Infections · United States1CompletedDec 17, 2025126
NCT06310551HIV Infections · United States1RecruitingMay 28, 2029348
NCT06310616HIV Infections · United States1CompletedAug 15, 202426
NCT06214052HIV Infections · United States, Argentina, Canada and more2CompletedJun 12, 202422
NCT05631704HIV Infections · United States1CompletedJul 27, 202384

How it is read

Names in the registry

  • “VH4524184”, 6 entries
  • “VH4524184 Formulation A IM”, 1 entry
  • “VH4524184 Formulation B IM”, 1 entry

Codes read as this program: VH4524184.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.